The Role of Cannabis and Cannabinoids in Pain Management (full – 2002) http://www.humanhemphealth.ca/Russo-AAPM_chapter.pdf
Marijuana-Derived Compound Targets Pain, Inflammation (news – 2002) http://www.sciencedaily.com/releases...0822071026.htm
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial (full – 2003) http://jama.ama-assn.org/cgi/content...urcetype=HWCIT
Ajulemic acid: A novel cannabinoid produces analgesia without a “high†(abst – 2004) http://www.ncbi.nlm.nih.gov/pubmed/1...?dopt=Abstract
Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials (full - 2005)http://www.ncbi.nlm.nih.gov/pmc/arti...5/?tool=pubmed
Marijuana-Derived Drug Suppresses Bladder Overactivity And Irritation In Animal Models (news - 2005)http://www.sciencedaily.com/releases...0906080225.htm
Cannabimimetic Properties of Ajulemic Acid (full – 2006) http://www.ncbi.nlm.nih.gov/pmc/arti...tool=pmcentrez
Marijuana-Derived Drug Suppresses Bladder Pain In Animal Models (news - 2006)http://www.sciencedaily.com/releases...0521103039.htm
Cannabimimetic Properties of Ajulemic Acid (full – 2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2633725/
In humans, ajulemic acid has a more favorable side-effect profile than THC for the treatment of chronic neuropathic pain (full - 2007)http://www.cannabis-med.org/english/..._2007_01_1.pdf
Letter: Preclinical assessment of abuse liability of ajulemic acid (letter – 2007) http://www.cannabis-med.org/english/..._2007_01_2.pdf
Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid (abst - 2007)http://www.ncbi.nlm.nih.gov/pubmed/16927387
Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats (abst - 2007)http://www.ncbi.nlm.nih.gov/pubmed/17656248
Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances (abst - 2007) http://www.ncbi.nlm.nih.gov/pubmed/17868014
Cannabinoids in the management of difficult to treat pain (full – 2008) http://www.ncbi.nlm.nih.gov/pmc/arti...tool=pmcentrez
Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells (abst - 2008) http://www.ncbi.nlm.nih.gov/pubmed/17786950
Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells (abst – 2008)http://www.ncbi.nlm.nih.gov/pubmed/18840450
Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid (abst - 2008)http://www.ncbi.nlm.nih.gov/pubmed/18040689
Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation (full – 2009) http://www.ncbi.nlm.nih.gov/pmc/arti...tool=pmcentrez
Cannabinoids as novel anti-inflammatory drugs (full – 2009) http://www.ncbi.nlm.nih.gov/pmc/arti...4/?tool=pubmed
Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4 (full – 2009) http://www.fasebj.org/cgi/content/fu...urcetype=HWCIT
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis (abst – 2012)http://www.ncbi.nlm.nih.gov/pubmed/22492781
In vitro metabolism and metabolic effects of ajulemic acid, a synthetic cannabinoid agonist (full – 2013)http://onlinelibrary.wiley.com/doi/10.1002/prp2.17/full
In vitro metabolism and metabolic effects of ajulemic acid, a synthetic cannabinoid agonist (full – 2013)http://onlinelibrary.wiley.com/doi/10.1002/prp2.17/full
Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/24121462
The cannabinoid acids, analogs and endogenous counterparts (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24731541
Inhibition of Voltage-Gated Na+ Channels by the Synthetic Cannabinoid Ajulemic Acid (abst – 2014)http://www.ncbi.nlm.nih.gov/pubmed/24755846
Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24856183
Marijuana-Derived Compound Targets Pain, Inflammation (news – 2002) http://www.sciencedaily.com/releases...0822071026.htm
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial (full – 2003) http://jama.ama-assn.org/cgi/content...urcetype=HWCIT
Ajulemic acid: A novel cannabinoid produces analgesia without a “high†(abst – 2004) http://www.ncbi.nlm.nih.gov/pubmed/1...?dopt=Abstract
Ajulemic acid (IP-751): Synthesis, proof of principle, toxicity studies, and clinical trials (full - 2005)http://www.ncbi.nlm.nih.gov/pmc/arti...5/?tool=pubmed
Marijuana-Derived Drug Suppresses Bladder Overactivity And Irritation In Animal Models (news - 2005)http://www.sciencedaily.com/releases...0906080225.htm
Cannabimimetic Properties of Ajulemic Acid (full – 2006) http://www.ncbi.nlm.nih.gov/pmc/arti...tool=pmcentrez
Marijuana-Derived Drug Suppresses Bladder Pain In Animal Models (news - 2006)http://www.sciencedaily.com/releases...0521103039.htm
Cannabimimetic Properties of Ajulemic Acid (full – 2007) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2633725/
In humans, ajulemic acid has a more favorable side-effect profile than THC for the treatment of chronic neuropathic pain (full - 2007)http://www.cannabis-med.org/english/..._2007_01_1.pdf
Letter: Preclinical assessment of abuse liability of ajulemic acid (letter – 2007) http://www.cannabis-med.org/english/..._2007_01_2.pdf
Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid (abst - 2007)http://www.ncbi.nlm.nih.gov/pubmed/16927387
Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats (abst - 2007)http://www.ncbi.nlm.nih.gov/pubmed/17656248
Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances (abst - 2007) http://www.ncbi.nlm.nih.gov/pubmed/17868014
Cannabinoids in the management of difficult to treat pain (full – 2008) http://www.ncbi.nlm.nih.gov/pmc/arti...tool=pmcentrez
Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells (abst - 2008) http://www.ncbi.nlm.nih.gov/pubmed/17786950
Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells (abst – 2008)http://www.ncbi.nlm.nih.gov/pubmed/18840450
Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid (abst - 2008)http://www.ncbi.nlm.nih.gov/pubmed/18040689
Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation (full – 2009) http://www.ncbi.nlm.nih.gov/pmc/arti...tool=pmcentrez
Cannabinoids as novel anti-inflammatory drugs (full – 2009) http://www.ncbi.nlm.nih.gov/pmc/arti...4/?tool=pubmed
Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4 (full – 2009) http://www.fasebj.org/cgi/content/fu...urcetype=HWCIT
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis (abst – 2012)http://www.ncbi.nlm.nih.gov/pubmed/22492781
In vitro metabolism and metabolic effects of ajulemic acid, a synthetic cannabinoid agonist (full – 2013)http://onlinelibrary.wiley.com/doi/10.1002/prp2.17/full
In vitro metabolism and metabolic effects of ajulemic acid, a synthetic cannabinoid agonist (full – 2013)http://onlinelibrary.wiley.com/doi/10.1002/prp2.17/full
Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists (abst – 2013)http://www.ncbi.nlm.nih.gov/pubmed/24121462
The cannabinoid acids, analogs and endogenous counterparts (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24731541
Inhibition of Voltage-Gated Na+ Channels by the Synthetic Cannabinoid Ajulemic Acid (abst – 2014)http://www.ncbi.nlm.nih.gov/pubmed/24755846
Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24856183